These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 34423318)

  • 1. Fluorogenic
    Ihssen J; Faccio G; Yao C; Sirec T; Spitz U
    STAR Protoc; 2021 Sep; 2(3):100793. PubMed ID: 34423318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the Main Protease of SARS-CoV-2: From the Establishment of High Throughput Screening to the Design of Tailored Inhibitors.
    Breidenbach J; Lemke C; Pillaiyar T; Schäkel L; Al Hamwi G; Diett M; Gedschold R; Geiger N; Lopez V; Mirza S; Namasivayam V; Schiedel AC; Sylvester K; Thimm D; Vielmuth C; Phuong Vu L; Zyulina M; Bodem J; Gütschow M; Müller CE
    Angew Chem Int Ed Engl; 2021 Apr; 60(18):10423-10429. PubMed ID: 33655614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protocol to identify flavonoid antagonists of the SARS-CoV-2 main protease.
    Yang M; Lin L; Flaumenhaft R
    STAR Protoc; 2024 Jun; 5(2):102990. PubMed ID: 38583157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors.
    Huff S; Kummetha IR; Tiwari SK; Huante MB; Clark AE; Wang S; Bray W; Smith D; Carlin AF; Endsley M; Rana TM
    J Med Chem; 2022 Feb; 65(4):2866-2879. PubMed ID: 34570513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 M
    Delgado R; Vishwakarma J; Moghadasi SA; Otsuka Y; Shumate J; Cuell A; Tansiongco M; Cooley CB; Chen Y; Dabrowska A; Basu R; Anindita PD; Luo D; Dosa PI; Harki DA; Bannister T; Scampavia L; Spicer TP; Harris RS
    SLAS Discov; 2024 Sep; 29(6):100181. PubMed ID: 39173830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
    Froggatt HM; Heaton BE; Heaton NS
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Updated Review on SARS-CoV-2 Main Proteinase (M
    Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
    Curr Top Med Chem; 2021; 21(6):442-460. PubMed ID: 33292134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved SARS-CoV-2 main protease high-throughput screening assay using a 5-carboxyfluorescein substrate.
    Legare S; Heide F; Bailey-Elkin BA; Stetefeld J
    J Biol Chem; 2022 Apr; 298(4):101739. PubMed ID: 35182525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An ISG15-Based High-Throughput Screening Assay for Identification and Characterization of SARS-CoV-2 Inhibitors Targeting Papain-like Protease.
    Samrat SK; Kumar P; Liu Y; Chen K; Lee H; Li Z; Chen Y; Li H
    Viruses; 2024 Aug; 16(8):. PubMed ID: 39205213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigallocatechin-3-gallate, an active ingredient of Traditional Chinese Medicines, inhibits the 3CLpro activity of SARS-CoV-2.
    Du A; Zheng R; Disoma C; Li S; Chen Z; Li S; Liu P; Zhou Y; Shen Y; Liu S; Zhang Y; Dong Z; Yang Q; Alsaadawe M; Razzaq A; Peng Y; Chen X; Hu L; Peng J; Zhang Q; Jiang T; Mo L; Li S; Xia Z
    Int J Biol Macromol; 2021 Apr; 176():1-12. PubMed ID: 33548314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioactive Terpenes and Their Derivatives as Potential SARS-CoV-2 Proteases Inhibitors from Molecular Modeling Studies.
    Diniz LRL; Perez-Castillo Y; Elshabrawy HA; Filho CDSMB; de Sousa DP
    Biomolecules; 2021 Jan; 11(1):. PubMed ID: 33430299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 M
    Rut W; Groborz K; Zhang L; Sun X; Zmudzinski M; Pawlik B; Wang X; Jochmans D; Neyts J; Młynarski W; Hilgenfeld R; Drag M
    Nat Chem Biol; 2021 Feb; 17(2):222-228. PubMed ID: 33093684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of highly potent SARS-CoV-2 M
    Chen W; Feng B; Han S; Wang P; Chen W; Zang Y; Li J; Hu Y
    Bioorg Med Chem Lett; 2022 Feb; 58():128526. PubMed ID: 34998903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances Toward COVID-19 Therapies Special Issue.
    Neamati N
    J Med Chem; 2022 Feb; 65(4):2713-2715. PubMed ID: 35138859
    [No Abstract]   [Full Text] [Related]  

  • 15. Potential SARS-CoV-2 protease M
    Kouznetsova VL; Huang DZ; Tsigelny IF
    Phys Biol; 2021 Feb; 18(2):025001. PubMed ID: 33203811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fragment-based Drug Discovery Strategy and its Application to the Design of SARS-CoV-2 Main Protease Inhibitor.
    Jiang Y; Wu Y; Wang J; Ma Y; Yu H; Wang Z
    Curr Med Chem; 2024; 31(38):6204-6226. PubMed ID: 38529602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based identification of SARS-CoV-2 main protease inhibitors from anti-viral specific chemical libraries: an exhaustive computational screening approach.
    Bhowmick S; Saha A; Osman SM; Alasmary FA; Almutairi TM; Islam MA
    Mol Divers; 2021 Aug; 25(3):1979-1997. PubMed ID: 33844135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a Cell-Based Luciferase Complementation Assay for Identification of SARS-CoV-2 3CL
    Rawson JMO; Duchon A; Nikolaitchik OA; Pathak VK; Hu WS
    Viruses; 2021 Jan; 13(2):. PubMed ID: 33498923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Dual-Color Fluorescent Probe Allows Simultaneous Imaging of Main and Papain-like Proteases of SARS-CoV-2-Infected Cells for Accurate Detection and Rapid Inhibitor Screening.
    Cheng Y; Borum RM; Clark AE; Jin Z; Moore C; Fajtová P; O'Donoghue AJ; Carlin AF; Jokerst JV
    Angew Chem Int Ed Engl; 2022 Feb; 61(9):e202113617. PubMed ID: 34889013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apigenin analogues as SARS-CoV-2 main protease inhibitors:
    Farhat A; Ben Hlima H; Khemakhem B; Ben Halima Y; Michaud P; Abdelkafi S; Fendri I
    Bioengineered; 2022 Feb; 13(2):3350-3361. PubMed ID: 35048792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.